JMCC Presents: Frontiers in Medical Cannabis Healthcare
May 12, 2021
Industry and medical leaders explore new delivery formats and the use of innovative technologies in patient assessment, treatment and monitoring as well as how healthcare specialists and private-sector organizations are collaborating to improve patient experiences and outcomes.
Part 1: Introduction & Patient Assessment
After JMCC Group Chair & CEO welcomes speakers and attendees, moderator Dr. Evan Cole Lewis of the Toronto Neurology Centre and Chief Medical Advisor to JMCC introduces Gregg Steinway, CEO of Greenway DNA. Gregg explains the science behind his company’s patent-pending DNA test, which uses a patient’s saliva sample to analyze 20 genes and 40 genetic variants associated with endocannabinoid responses that have a scientifically proven effect on the body. This gives medical cannabis prescribers and patients a precise starting point for CBD and/or THC dosing recommendations for a range of conditions.
Part 2: New Delivery Formats for Improved Bioavailability & At the Pharmacy: Compounding & Patient Monitoring
JMCC Scientific Managing Director Anton Mattadeen explains the role of bioavailability in medical cannabis treatment and the relative bioavailability of different delivery formats – from smoking dried flower, to vaping, tinctures and others. Then he describes the science and technology behind nano-emulsified sprays and the pharmacokinetic studies that have proven their superior bioavailability, dosing precision and ease of use for patients.
Then Rahim Dhalla, CEO, Pharmacist, Medical Cannabis Consultant at Hybrid Pharm, describes his cannabis- and patient-centric pharmacy in Ottawa, Ontario. He discusses some of the issues around Canada’s current medical cannabis system and how too many patients are getting erroneous information from family members, friends and the Internet, then buying their cannabis from the retail channel – without seeing a medical professional for consultation, guidance and follow-up – and the role that trained and experienced pharmacists can play in ongoing patient monitoring. He also describes how compounding cannabis to meet the individual needs of patients can lead to better treatment with fewer side effects.